Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Targovax ASA ( (GB:0RIS) ) has shared an announcement.
Circio Holding ASA announced significant advancements in their AAV-circVec technology, demonstrating a 40-fold increase in protein expression in heart tissue compared to conventional mRNA-based AAV gene delivery. This breakthrough, presented at the ESGCT annual meeting, highlights the potential of circVec to transform gene therapy by offering enhanced safety and reduced treatment costs, positioning it as a novel gold-standard gene expression system.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in the development of circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform is designed for efficient biogenesis of multifunctional circRNA inside target cells, with applications in genetic medicine, cell therapy, and chronic disease.
Average Trading Volume: 553,464
Current Market Cap: NOK69.11M
For an in-depth examination of 0RIS stock, go to TipRanks’ Overview page.